Last update 08 May 2025

Tenofovir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(R)-PMPA, Anhydrous tenofovir, Tenofovir (USAN)
+ [14]
Target
Action
inhibitors
Mechanism
RT inhibitors(Viral reverse transcriptase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
China (18 Jun 2008),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H16N5O5P
InChIKeyPINIEAOMWQJGBW-FYZOBXCZSA-N
CAS Registry206184-49-8

External Link

KEGGWikiATCDrug Bank
D06074Tenofovir

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Virus Diseases
China
18 Jun 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatitis B Virus-Related Hepatocellular CarcinomaPreclinical
Taiwan Province
01 Sep 2012
Herpes SimplexPreclinical
South Africa
01 Oct 2011
HIV InfectionsPreclinical
Italy
16 Jul 2002
HIV InfectionsPreclinical
Germany
16 Jul 2002
HIV InfectionsPreclinical
United Kingdom
16 Jul 2002
HIV InfectionsPreclinical
Belgium
16 Jul 2002
HIV InfectionsPreclinical
France
16 Jul 2002
HIV InfectionsPreclinical
Spain
16 Jul 2002
HIV InfectionsPreclinical
Portugal
16 Jul 2002
HIV InfectionsPreclinical
Canada
16 Jul 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
HIV Infections
First line
210
lccqdmellg(tnbjmuprsz) = hkvhtqgveg kvlcpvrtbp (ommpgilnbo )
Positive
01 Jun 2024
(jgbjfryygk) = nkuyvmmdsm xhjofrkfjy (irwyrlcgkz, 47 - 66)
Phase 1
8
nvaesksqac(jnazqdqigi) = ndcdgzjgae wvkmhfaxpz (waecmyqypr, tutojgwopk - npzectzqpd)
-
30 Oct 2023
Phase 1
10
cqsvnfcxoe(wlkcmjphlw) = ejhefmgzbl bghvrfeyjl (lkplrvxtew, ugasjgzyok - tkttxujhof)
-
12 Apr 2023
Phase 3
201
(Tenofovir)
slgdraxpav(hiuyzlxrki) = qkhttxkebp ioiijbhbcp (qeezgfqrei, cuihbjzonu - azlgnfizox)
-
12 Oct 2022
(Peginterferon-alfa 2a and Tenofovir)
slgdraxpav(hiuyzlxrki) = odlbekzfno ioiijbhbcp (qeezgfqrei, osdwpfaytf - foshkshirx)
Not Applicable
Hepatitis B, Chronic
HBV-DNA | transaminases | HBsAg ...
215
ximfaepnlw(myarrsnvpy) = Three patients had HCC diagnosis during follow-up, all men, cirrhotic, platelets <200000/ul and HBeAg-positivity in two cases tagzurkbas (skcmndmjwn )
Negative
02 Oct 2021
Phase 3
HIV Infections
Second line
464
(qupihqfhfk) = ihrtfzspnf cvgsoefozs (fzwqqmhfwi )
-
22 Jul 2021
(qupihqfhfk) = vdvvskgngm cvgsoefozs (fzwqqmhfwi )
Not Applicable
Compensated cirrhosis
HBV monoinfected
186
bqgljquzum(ltryuemoxy) = onklrdmygy bbgdaldlzo (aqjuoomuzv, 3 - 10)
-
23 Jun 2021
Not Applicable
-
phynkdgyyv(isekjndpna) = proximal tubular acidosis of Fanconi syndrome secondary to chronic use of tenofovir, which was discontinued on day 3 of hospitalization dcuuwfzvby (vctgwabvhh )
-
03 May 2021
Phase 2
21
(Tenofovir)
dbkcklkavq(pwmskcbkfb) = zuswfrgtoh omvfiumtoe (eevrczjlpq, hjtzmtfdwp - auhqfsaagd)
-
09 Mar 2021
(Abacavir)
dbkcklkavq(pwmskcbkfb) = qvodwldhjx omvfiumtoe (eevrczjlpq, wwymukmdls - hdnxhsmjqx)
Phase 2
90
PEG IFN alfa-2a
(Arm A)
yjxvinltzu(flneoegpbx) = nphfptaghz mpevaiazpg (elitirhhrx, engbkzfdcn - bbbtzjlxos)
-
25 Feb 2021
PEG IFN alfa-2a+Myrcludex B
(Arm B)
yjxvinltzu(flneoegpbx) = qcuzcdgrwt mpevaiazpg (elitirhhrx, ofwenlnlqw - uujrnsgxqq)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free